Alaunos Therapeutics, Inc. (TCRT)
Largest Insider Buys in Sector
TCRT Stock Price History Chart
TCRT Stock Performance
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, …
Insider Activity of Alaunos Therapeutics, Inc.
Over the last 12 months, insiders at Alaunos Therapeutics, Inc. have bought $0 and sold $0 worth of Alaunos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Alaunos Therapeutics, Inc. have bought $969,543 and sold $415,735 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750,000 shares for transaction amount of $487,500 was made by Postma Robert W (director) on 2022‑11‑29.
List of Insider Buy and Sell Transactions, Alaunos Therapeutics, Inc.
| 2023-09-01 | Sale | Chief Executive Officer | 68,014 0.0277% | $0.14 | $9,542 | -40.66% | ||
| 2022-11-29 | director | 750,000 0.3334% | $0.65 | $487,500 | -26.47% | |||
| 2022-11-29 | director | 1.25M 0.5557% | $0.65 | $812,500 | -26.47% | |||
| 2021-12-22 | Sale | EVP, Operations | 20,132 0.0094% | $1.27 | $25,568 | -25.70% | ||
| 2021-11-17 | Chief Executive Officer | 9,116 0.0044% | $1.40 | $12,762 | -20.22% | |||
| 2021-11-16 | Chief Executive Officer | 884 0.0004% | $1.40 | $1,238 | -22.70% | |||
| 2021-09-29 | director | 100,000 0.0464% | $1.91 | $191,000 | -40.63% | |||
| 2021-09-02 | director | 75,000 0.0342% | $1.73 | $129,750 | -35.59% | |||
| 2021-09-02 | director | 23,770 0.011% | $1.76 | $41,835 | -35.59% | |||
| 2021-09-01 | director | 50,000 0.0238% | $1.83 | $91,500 | -36.31% | |||
| 2021-09-01 | director | 100,000 0.0445% | $1.71 | $171,000 | -36.31% | |||
| 2021-01-08 | Sale | EVP, GM Gene Therapy | 27,894 0.0129% | $3.12 | $87,029 | -22.47% | ||
| 2021-01-08 | Sale | General Counsel and Secretary | 26,500 0.0122% | $3.12 | $82,680 | -22.47% | ||
| 2021-01-08 | Sale | SVP, Treasurer & CAO | 18,020 0.0082% | $3.09 | $55,682 | -22.47% | ||
| 2021-01-04 | Sale | President and CEO | 105,693 0.0475% | $2.71 | $286,428 | -9.93% | ||
| 2021-01-04 | Sale | EVP, GM Cell Therapy | 21,620 0.0097% | $2.72 | $58,806 | -9.93% | ||
| 2020-01-02 | Sale | President | 22,394 0.011% | $4.55 | $101,893 | -37.61% | ||
| 2020-01-02 | Sale | EVP, GM Cell Therapy | 24,890 0.0123% | $4.55 | $113,250 | -37.61% | ||
| 2020-01-02 | Sale | EVP, GM Gene Therapy | 27,923 0.0138% | $4.55 | $127,050 | -37.61% | ||
| 2020-01-02 | Sale | General Counsel and Secretary | 16,853 0.0083% | $4.55 | $76,681 | -37.61% |
Insider Historical Profitability
| Postma Robert W | director | 5000000 312.256% | $1.96 | 2 | 0 | <0.0001% |
| Cooper Laurence James Neil | President and CEO | 1799280 112.3672% | $1.96 | 1 | 2 | <0.0001% |
| Vieser Jaime | director | 1250000 78.064% | $1.96 | 2 | 0 | <0.0001% |
| Boyle Kevin S. Sr. | Chief Executive Officer | 798236 49.8508% | $1.96 | 2 | 1 | <0.0001% |
| MAUNEY DAVID M MD | President | 195278 12.1953% | $1.96 | 1 | 1 | <0.0001% |